Navigation Links
New Anti-Clotting Drug Less Risky For Heart Attack Patients

A new study has found anti-clotting drug called bivalirudin (Angiomax) that beats the standard combination drug therapy for patients with acute coronary syndromes such as heart// attacks. This new blood thinner seems to be less risky for patients suffering from acute coronary syndromes.

The Results of the ‘Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial’ were published in November issue of the New England Journal of Medicine. The Medicines Company and Nycomed, which market Angiomax, funded the study. A team lead by Dr. Gregg W. Stone, a professor of medicine and director of cardiovascular research and education are conducting the research.

Dr. Stone said: "We use bivalirudin at Columbia in the vast majority of cases and have found out that compared to heparin, it is just as effective and safely allows us to do angioplasty with a major reduction in bleeding episodes."

The journal described a trial that involved around 14,000 patients with heart attack or other acute coronary syndromes. The patients were assigned to one of three drug regimens: a package treatment including heparin; a similar package including bivalirudin; or bivalirudin alone. The results showed that the patients treated with Angiomax, also known as bivalirudin, had similar rates of serious complications, such as death, heart attack and repeat artery clearing procedures as the other groups, but had significantly lower rates of serious bleeding.

Only 3 percent of those getting bivalirudin alone had major bleeding episodes comparing to that of 5.7 percent of those getting the heparin package, for patients, that makes all the difference, Stone said. Moreover, the researchers were able find that the incidences of artery blockages or major bleeding were also reduced by the usage of bivalirudin by about 14 percent compared to a drug package including heparin.

"The big difference was the reduction of major bleeding, almost 50 percent," Stone added. "Major bleeding has been associated with higher mortality, so it is important that bivalirudin, which reduced the risk of major bleeding up to 47 percent, could be reserved for patients with history of bleeding such as anemia.” – He added.

To conclude, the drug has been currently approved as a replacement for heparin in all nonemergency angioplasty procedures.
RI
'"/>




Related medicine news :

1. FDA Approves New Anti-Clotting Drug
2. Herbal Remedy Risky for Cancer Patients
3. Risky Drugs To Be Avoided In The Elderly
4. HRT Not That Risky For Breast Cancer
5. Coffee In Pregnancy May Be Risky: Study
6. Distinct Brain Sections Are Activated While Making Risky Decisions
7. Americans Avoiding Risky Foods
8. Heavy Dosage Of Vitamin Supplements May Be Risky For Pregnant Women
9. Males Show More Risky Behaviour with Alcohol
10. Risky Behavior In Teenagers Leads To Depression
11. Insight Into The Risky Health Decisions On Bird Flu
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the ... for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center ... Market Committee (FOMC) dot charts are of interest to the press for their noise ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology: